StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)

Equities researchers at StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN) in a research report issued to clients and investors on Sunday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Trading Up 0.9 %

NASDAQ LPCN opened at $4.36 on Friday. The firm has a market cap of $23.33 million, a price-to-earnings ratio of -5.74 and a beta of 1.23. The company has a 50 day moving average of $4.78 and a 200-day moving average of $4.78. Lipocine has a 1-year low of $3.20 and a 1-year high of $11.79.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter.

Institutional Trading of Lipocine

An institutional investor recently raised its position in Lipocine stock. Renaissance Technologies LLC lifted its stake in Lipocine Inc. (NASDAQ:LPCN) by 21.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,697 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,600 shares during the period. Renaissance Technologies LLC owned 0.48% of Lipocine worth $212,000 at the end of the most recent quarter. Institutional investors and hedge funds own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.